Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

COR vs HSIC vs MCK vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
COR
Cencora, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$50.80B
5Y Perf.+173.8%
HSIC
Henry Schein, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8.13B
5Y Perf.+16.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$90.21B
5Y Perf.+364.2%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.22B
5Y Perf.+235.8%

COR vs HSIC vs MCK vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
COR logoCOR
HSIC logoHSIC
MCK logoMCK
CAH logoCAH
IndustryMedical - DistributionMedical - DistributionMedical - DistributionMedical - Distribution
Market Cap$50.80B$8.13B$90.21B$43.22B
Revenue (TTM)$328.68B$13.18B$403.43B$250.55B
Net Income (TTM)$2.55B$398M$4.76B$1.56B
Gross Margin3.5%29.1%3.6%3.7%
Operating Margin1.2%5.8%1.5%0.9%
Forward P/E14.7x13.2x16.7x17.1x
Total Debt$10.75B$3.69B$8.61B$9.35B
Cash & Equiv.$4.39B$156M$3.98B$3.87B

COR vs HSIC vs MCK vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

COR
HSIC
MCK
CAH
StockMay 20May 26Return
Cencora, Inc. (COR)100273.8+173.8%
Henry Schein, Inc. (HSIC)100116.6+16.6%
McKesson Corporation (MCK)100464.2+364.2%
Cardinal Health, In… (CAH)100335.8+235.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: COR vs HSIC vs MCK vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HSIC and MCK are tied at the top with 2 categories each — the right choice depends on your priorities. McKesson Corporation is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. CAH and COR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
COR
Cencora, Inc.
The Income Pick

COR is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 24 yrs, beta 0.00, yield 0.9%
  • Lower volatility, beta 0.00, current ratio 0.90x
  • Beta 0.00 vs HSIC's 0.72
Best for: income & stability and sleep-well-at-night
HSIC
Henry Schein, Inc.
The Value Play

HSIC has the current edge in this matchup, primarily because of its strength in value and quality.

  • Lower P/E (13.2x vs 17.1x)
  • 3.0% margin vs CAH's 0.6%
Best for: value and quality
MCK
McKesson Corporation
The Growth Play

MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
  • 339.0% 10Y total return vs COR's 276.7%
  • PEG 0.43 vs HSIC's 4.20
  • 12.4% revenue growth vs CAH's -1.9%
Best for: growth exposure and long-term compounding
CAH
Cardinal Health, Inc.
The Defensive Pick

CAH is the clearest fit if your priority is defensive.

  • Beta 0.01, yield 1.1%, current ratio 0.94x
  • 1.1% yield, 20-year raise streak, vs COR's 0.9%, (1 stock pays no dividend)
  • +26.1% vs COR's -7.2%
Best for: defensive
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK12.4% revenue growth vs CAH's -1.9%
ValueHSIC logoHSICLower P/E (13.2x vs 17.1x)
Quality / MarginsHSIC logoHSIC3.0% margin vs CAH's 0.6%
Stability / SafetyCOR logoCORBeta 0.00 vs HSIC's 0.72
DividendsCAH logoCAH1.1% yield, 20-year raise streak, vs COR's 0.9%, (1 stock pays no dividend)
Momentum (1Y)CAH logoCAH+26.1% vs COR's -7.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs CAH's 2.8%, ROIC 74.5% vs 33.8%

COR vs HSIC vs MCK vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CORCencora, Inc.
FY 2025
Pharmaceutical Distribution
88.8%$285.3B
International Healthcare Solutions
9.4%$30.4B
Animal Health
1.8%$5.7B
HSICHenry Schein, Inc.
FY 2018
Healthcare Distribution
96.1%$12.7B
Technology
3.9%$509M
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

COR vs HSIC vs MCK vs CAH — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHSICLAGGINGCOR

Income & Cash Flow (Last 12 Months)

HSIC leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 30.6x HSIC's $13.2B. Profitability is closely matched — net margins range from 3.0% (HSIC) to 0.6% (CAH). On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCOR logoCORCencora, Inc.HSIC logoHSICHenry Schein, Inc.MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$328.7B$13.2B$403.4B$250.5B
EBITDAEarnings before interest/tax$5.0B$1.1B$6.8B$3.2B
Net IncomeAfter-tax profit$2.5B$398M$4.8B$1.6B
Free Cash FlowCash after capex$1.6B$561M$6.0B$4.4B
Gross MarginGross profit ÷ Revenue+3.5%+29.1%+3.6%+3.7%
Operating MarginEBIT ÷ Revenue+1.2%+5.8%+1.5%+0.9%
Net MarginNet income ÷ Revenue+0.8%+3.0%+1.2%+0.6%
FCF MarginFCF ÷ Revenue+0.5%+4.3%+1.5%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+3.8%+7.7%+6.0%+11.0%
EPS Growth (YoY)Latest quarter vs prior year+128.3%+14.9%+37.0%-19.5%
HSIC leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

HSIC leads this category, winning 4 of 7 comparable metrics.

At 19.2x trailing earnings, MCK trades at a 41% valuation discount to COR's 32.8x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.43x vs HSIC's 6.87x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCOR logoCORCencora, Inc.HSIC logoHSICHenry Schein, Inc.MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Market CapShares × price$50.8B$8.1B$90.2B$43.2B
Enterprise ValueMkt cap + debt − cash$57.1B$11.7B$94.9B$48.7B
Trailing P/EPrice ÷ TTM EPS32.80x21.66x19.19x28.47x
Forward P/EPrice ÷ next-FY EPS est.14.74x13.25x16.66x17.09x
PEG RatioP/E ÷ EPS growth rate6.87x0.43x
EV / EBITDAEnterprise value multiple12.14x10.90x15.27x15.88x
Price / SalesMarket cap ÷ Revenue0.16x0.62x0.22x0.19x
Price / BookPrice ÷ Book value/share29.17x1.80x11.63x
Price / FCFMarket cap ÷ FCF15.84x14.18x14.66x23.36x
HSIC leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $8 for HSIC. HSIC carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to COR's 6.15x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs HSIC's 4/9, reflecting strong financial health.

MetricCOR logoCORCencora, Inc.HSIC logoHSICHenry Schein, Inc.MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity+105.8%+8.2%+3.0%
ROA (TTM)Return on assets+3.3%+3.6%+5.7%+2.8%
ROICReturn on invested capital+44.5%+7.1%+74.5%+33.8%
ROCEReturn on capital employed+23.1%+9.8%+43.1%+19.2%
Piotroski ScoreFundamental quality 0–96476
Debt / EquityFinancial leverage6.15x0.77x1.10x
Net DebtTotal debt minus cash$6.4B$3.5B$4.6B$5.5B
Cash & Equiv.Liquid assets$4.4B$156M$4.0B$3.9B
Total DebtShort + long-term debt$10.7B$3.7B$8.6B$9.3B
Interest CoverageEBIT ÷ Interest expense3.73x4.59x33.79x6.38x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CAH leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $8,536 for HSIC. Over the past 12 months, CAH leads with a +26.1% total return vs COR's -7.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.1% vs HSIC's -3.9% — a key indicator of consistent wealth creation.

MetricCOR logoCORCencora, Inc.HSIC logoHSICHenry Schein, Inc.MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date-22.8%-7.8%-10.5%-10.2%
1-Year ReturnPast 12 months-7.2%+2.8%+7.2%+26.1%
3-Year ReturnCumulative with dividends+59.0%-11.3%+102.1%+125.5%
5-Year ReturnCumulative with dividends+120.0%-14.6%+270.4%+232.0%
10-Year ReturnCumulative with dividends+276.7%+5.8%+339.0%+158.8%
CAGR (3Y)Annualised 3-year return+16.7%-3.9%+26.4%+31.1%
CAH leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — HSIC and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than HSIC's 0.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HSIC currently trades 79.3% from its 52-week high vs COR's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCOR logoCORCencora, Inc.HSIC logoHSICHenry Schein, Inc.MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5000.00x0.72x-0.02x0.01x
52-Week HighHighest price in past year$377.54$89.29$999.00$233.60
52-Week LowLowest price in past year$244.82$61.95$637.00$137.75
% of 52W HighCurrent price vs 52-week peak+69.2%+79.3%+73.7%+78.6%
RSI (14)Momentum oscillator 0–10019.534.321.028.6
Avg Volume (50D)Average daily shares traded1.5M1.2M782K1.8M
Evenly matched — HSIC and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — COR and CAH each lead in 1 of 2 comparable metrics.

Analyst consensus: COR as "Buy", HSIC as "Hold", MCK as "Buy", CAH as "Buy". Consensus price targets imply 54.5% upside for COR (target: $403) vs 20.6% for HSIC (target: $85). For income investors, CAH offers the higher dividend yield at 1.11% vs MCK's 0.42%.

MetricCOR logoCORCencora, Inc.HSIC logoHSICHenry Schein, Inc.MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuy
Price TargetConsensus 12-month target$403.29$85.43$994.86$253.38
# AnalystsCovering analysts46323133
Dividend YieldAnnual dividend ÷ price+0.9%+0.4%+1.1%
Dividend StreakConsecutive years of raises2411820
Dividend / ShareAnnual DPS$2.24$3.07$2.04
Buyback YieldShare repurchases ÷ mkt cap+0.9%+10.5%0.0%+1.8%
Evenly matched — COR and CAH each lead in 1 of 2 comparable metrics.
Key Takeaway

HSIC leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). MCK leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallHenry Schein, Inc. (HSIC)Leads 2 of 6 categories
Loading custom metrics...

COR vs HSIC vs MCK vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is COR or HSIC or MCK or CAH a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Cencora, Inc. (COR) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — COR or HSIC or MCK or CAH?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 19.

2x versus Cencora, Inc. at 32. 8x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — COR or HSIC or MCK or CAH?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -14. 6% for Henry Schein, Inc. (HSIC). Over 10 years, the gap is even starker: MCK returned +339. 0% versus HSIC's +5. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — COR or HSIC or MCK or CAH?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Henry Schein, Inc. 's 0. 72β — meaning HSIC is approximately -4519% more volatile than MCK relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 6% for Cencora, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — COR or HSIC or MCK or CAH?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to 5. 7% for Cencora, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — COR or HSIC or MCK or CAH?

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus 0. 5% for Cencora, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus 1. 0% for CAH. At the gross margin level — before operating expenses — HSIC leads at 29. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is COR or HSIC or MCK or CAH more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 17. 1x for Cardinal Health, Inc. — 3. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COR: 54. 5% to $403. 29.

08

Which pays a better dividend — COR or HSIC or MCK or CAH?

In this comparison, CAH (1.

1% yield), COR (0. 9% yield), MCK (0. 4% yield) pay a dividend. HSIC does not pay a meaningful dividend and should not be held primarily for income.

09

Is COR or HSIC or MCK or CAH better for a retirement portfolio?

For long-horizon retirement investors, Cencora, Inc.

(COR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00), 0. 9% yield, +276. 7% 10Y return). Both have compounded well over 10 years (COR: +276. 7%, HSIC: +5. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between COR and HSIC and MCK and CAH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

COR, CAH pay a dividend while HSIC, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

COR

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

HSIC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform COR and HSIC and MCK and CAH on the metrics below

Revenue Growth>
%
(COR: 3.8% · HSIC: 7.7%)
P/E Ratio<
x
(COR: 32.8x · HSIC: 21.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.